Reimbursement of diagnostic testing for COVID-19 in Europe
Syndicated report on reimbursement status of IVD tests for COVID-19 as of April 2020 in six European countries
COVID-19 pandemic seriously affected European countries. One of the key aspects of managing the epidemic is the timely testing of potentially infected people.
This report summarizes the reimbursement situation for COVID-19 in European countries with established reimbursement framework for in-vitro diagnostic tests (Belgium, France, Germany, Netherlands, Switzerland and Turkey).
The 26-page report answers the following question:
- Is there any reimbursement for IVD testing for COVID-19?
- What kind of tests (e.g. PCR or serology) are reimbursed?
- What are the reimbursement tariffs?
- Are there any restrictions for testing?
Key features of the report
6 EU countries
Reimbursement situation is summarized in the countries, where specific reimbursement frameworks exist (Belgium, France, Germany, Netherlands, Switzerland, Turkey)
Brief overview of system
Brief overview of reimbursement framework in each country is provided
Reimbursement situation for COVID-19 testing
Reimbursement codes and tariffs, testing restrictions and guidelines
Obtain sample pages
Click to the link below to obtain sample pages, including description of the reimbursement framework and reimbursement situation for COVID-19 in Switzerland
Get sample pages
Sources for analysis
Belgium: IVD tests included in the INAMI Nomenclature
France: IVD tests included in the NABM and RIHN Nomenclatures
Germany: IVD tests included in the EBM Nomenclature
Netherlands: Coverage policies by key insurance companies, decisions of Dutch Healthcare Authority and OZP List
Switzerland: IVD tests included in the List of Analyses (Annex 3 of the KLV List)
Turkey: IVD tests included in the Healthcare Implementation Communique
Request a quote
Click the button below to request a quote for the report
